ArticlePediatrics international : official journal of the Japan Pediatric Society
Blood Glucose Monitoring in the Neonatal Period: A Study on Evaluation Using the RAPIDPoint 500/500e.
Article in Pediatrics international : official journal of the Japan Pediatric Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRapid glucose assessment is essential in neonatal intensive care units (NICUs) for early detection of hypoglycemia. We evaluated the agreement between neonatal blood glucose levels measured using bedside blood gas analyzers (GasBS) and those measured in the central laboratory (LabBS), and identified factors associated with clinically significant discrepancies.
methodsWe retrospectively analyzed 5436 paired specimens from 2105 infants admitted to the NICU. For the primary agreement analyses, 5375 specimens with GasBS > 20 mg/dL were included. Agreement between GasBS and LabBS was assessed using Bland-Altman analysis, correlation analysis, and linear mixed models. Factors associated with clinically significant discrepancies (absolute difference ≥ 10 mg/dL) were evaluated using generalized linear mixed models. Exploratory receiver operating characteristic analysis was performed to assess the ability of GasBS to detect LabBS < 40 mg/dL.
resultsGasBS and LabBS showed good agreement, with a mean difference of 1.88 mg/dL (95% limits of agreement, -12.56 to 16.32 mg/dL) and a strong correlation (Spearman's ρ = 0.939, p < 0.001). Lower base excess, lower oxygenated hemoglobin, and higher postnatal age were associated with greater discrepancies, whereas higher hematocrit was associated with an increased risk of clinically significant discrepancies. GasBS also showed excellent performance in detecting LabBS < 40 mg/dL, with an area under the receiver operating characteristic curve of 0.985 and an optimal cutoff of 43.5 mg/dL.
conclusionsBlood gas analyzers provide clinically useful glucose measurements in newborns. However, discrepancies from central laboratory measurements may occur under certain physiological conditions, and confirmatory testing remains essential when severe hypoglycemia is suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.